Clinical Study of Cetuximab Combined with Radiotherapy and Chemotherapy for Treating Advanced Nasopharyngeal Carcinoma

T. Lin,C. Zhao,L. Gao,J. Y. Lang,J. J. Pan,C. S. Hu,F. Jin,R. S. Wang,C. H. Xie,T. X. Lu

DOI: https://doi.org/10.3969/j.issn.1007-3639.2009.02.014

2009-01-01

Abstract:Background and purpose:Recently study,cetuximab combined with radiotherapy reduced the rate of death for local advanced head and neck cancer when compared with radiotherapy alone.To realize it's utilization in nasopharyngeal carcinoma(NPC),in this study we explored the side effects and efficiencies of cetuximab when it was used combined with radiotherapy and chemotherapy for advanced NPC.Methods:12 patients with NPC were treated with cetuximab which was used concurrently with radiotherapy and chemotherapy.Cetuximab was given to an initial dose of 400 mg/m2 in the first week followed by weekly injection of 250 mg/m2.Untreated or locally recurrent NPC received intensity-modulated radiotherapy(IMRT),a dose of 6 975 cGy by 31 times in 6.2 weeks were given to the GTV in nasopharynx.Conventional technology was used for the metastatic tumor of NPC,a dose of 3 000 cGy by 10 times in 2 weeks were given.Results:Two patients with metastatic NPC after radical radiotherapy discontinued cetuximab because of disease progression.Two new NPC cases discontinued cetuximab because of grades Ⅲ mucositis of tongue.Two patients were delayed for one week of giving cetuximab because of grade Ⅲ rash.The rest 6 patients completed the planned treatment.The main side effects were acne-like or maculopapular rash,paronychia,stomatitis,and asthenia et al.10 patients received cetuximab concurrently with IMRT of nasopharynx,5 patients had grade Ⅲ mucositis of oropharynx and in which 4 patients had specific grade Ⅲ mucositis of tongue.At a median follow-up of 14 months,two patients with metastatic NPC after radical radiotherapy were died,10 patients including 4 metastatic NPC obtained disease-free survival.Conclusion:cetuximab combined with radiotherapy and chemotherapy was efficientand safe for advanced nasopharyngeal carcinoma.When cetuximab was used concurrently with IMRT in cancer of the nasopharynx,we observed specific grade Ⅲ mucositis of tongue which caused the planned treatment to be discontinued,Further clinical study is needed.